4.6 Article

Ascorbate uptake enables tubular mitophagy to prevent septic AKI by PINK1-PARK2 axis

期刊

出版社

ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.bbrc.2021.03.103

关键词

Ascorbate; Mitophagy; Septic AKI; PINK1-PARK2 axis

资金

  1. Natural Science Foundation of Zhejiang Province [LY19H020001, LQ20H150009]
  2. National Natural Science Foundation of China [81971857]
  3. Zhejiang Key R&D Project of Science Technology Department of Zhejiang Province [2019C03024]

向作者/读者索取更多资源

This study revealed that activation of Toll-like receptor 4 (TLR4) by LPS stimuli can enhance the uptake of ascorbate in renal tubular cells, providing protection against LPS-induced apoptosis. Additionally, ascorbate administration promotes mitophagy, aiding in the fight against septic acute kidney injury.
Ascorbate (Vitamin C) has been proposed as a promising therapeutic agent against sepsis in clinical trials, but there is little experimental evidence on its anti-septic efficacy. We report that Toll-like receptor 4 (TLR4) activation by LPS stimuli augments ascorbate uptake in murine and human tubular cells through upregulation of two ascorbate transporters SVCT-1 and -2 mediated by Fn14/SCFFbxw7 alpha cascade. Ascorbate restriction, or knockout of SVCT-1 and -2, the circumstance reminiscent to blockade of ascorbate uptake, endows tubular cells more vulnerable to the LPS-inducible apoptosis, whereas exogenous administration of ascorbate overrides the ruin execution, for which the PINK1-PARK2, rather than BNIP3-NIX axis is required. Ascorbate increases, while SVCT-1 and -2 knockout or ascorbate restriction dampens tubular mitophagy upon LPS stimuli. Treatment of endotoxemic mice with high-dose ascorbate confers mitophagy and substantial protection against mortality and septic acute kidney injury (AKI). Our work provides a rationale for clinical management of septic AKI with high doses of ascorbate. (C) 2021 Elsevier Inc. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据